Spots Global Cancer Trial Database for Study With Atu027 in Patients With Advanced Solid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Atu027 in Patients With Advanced Solid Cancer
Official Title: A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer
Study ID: NCT00938574
Conditions
Interventions
Study Description
Brief Summary: This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as therapy in subjects with advanced solid cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dept. of Hematology & Med. Oncology, Univ. of Bochum, Marienhospital Herne, Herne, , Germany
Contact Details
Name: Dirk Strumberg,, MD, Prof., Director
Affiliation: Dept. of Hematology & Med. Oncology, Univ. of Bochum, Marienhospital Herne
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
